Published in Curr Top Microbiol Immunol on January 01, 2010
Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol (2013) 3.57
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol (2013) 1.59
Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells. Oncotarget (2016) 0.77
Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics. Transl Oncogenomics (2016) 0.76
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
AKT/PKB signaling: navigating downstream. Cell (2007) 31.26
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
The phosphoinositide 3-kinase pathway. Science (2002) 24.72
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19
Defining the role of mTOR in cancer. Cancer Cell (2007) 21.63
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol (2008) 20.89
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet (2006) 17.19
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol (2004) 16.83
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med (2004) 13.57
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature (2006) 12.13
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 11.21
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet (2005) 11.05
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature (2007) 10.98
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest (2008) 10.74
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther (2008) 10.35
A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell (2006) 10.06
The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol (2004) 9.71
Tenets of PTEN tumor suppression. Cell (2008) 8.61
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A (2001) 6.99
Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell (2007) 6.44
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell (2009) 6.02
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res (2008) 5.82
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res (2007) 5.54
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med (2008) 5.54
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res (2009) 4.81
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci U S A (2001) 4.62
Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci (1997) 4.52
Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res (2002) 4.36
Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest (2008) 4.13
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol (2009) 4.12
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One (2008) 4.12
Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature (2006) 3.71
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res (2008) 3.70
Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol (2005) 3.62
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res (2009) 3.59
PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest (2007) 3.54
PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res (2007) 3.51
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol (2005) 3.41
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene (2003) 3.32
Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene (2008) 3.31
Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res (2006) 3.31
Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature (2008) 3.19
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res (2009) 3.14
Mutation of the PIK3CA oncogene in human cancers. Br J Cancer (2006) 3.04
The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene (2008) 2.66
Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer (2002) 2.44
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol (2007) 2.34
Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. Clin Cancer Res (2003) 2.33
A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res (2008) 2.30
PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. Cancer Res (2008) 2.20
Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res (2008) 2.15
Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res (2008) 2.15
Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res (2005) 2.14
Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res (2004) 2.14
Linking somatic genetic alterations in cancer to therapeutics. Curr Opin Cell Biol (2009) 2.11
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists. J Clin Oncol (2005) 2.04
HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res (2008) 1.63
Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression. Cancer Res (2007) 1.55
Mechanism and management of AKT inhibitor-induced hyperglycemia. Clin Cancer Res (2009) 1.53
mTOR inhibitors in the treatment of cancer. Expert Opin Investig Drugs (2008) 1.47
Should individual PI3 kinase isoforms be targeted in cancer? Curr Opin Cell Biol (2009) 1.47
Class 1A PI3K regulates vessel integrity during development and tumorigenesis. Proc Natl Acad Sci U S A (2008) 1.46
Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res (1994) 1.43
Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiol Biomarkers Prev (2001) 1.27
A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera. J Mol Biol (2007) 1.20
HER3 and mutant EGFR meet MET. Nat Med (2007) 1.19
The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. Eur J Cancer (2006) 1.16
Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer. Breast Cancer Res Treat (2003) 1.13
Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discovery. Expert Opin Ther Targets (2008) 1.13
Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT/PKB: mechanistic involvement of AKT catalytic activation loop cysteines. Mol Cancer Ther (2007) 0.98
Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer. Clin Cancer Res (2000) 0.91